<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-143337" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Small Interfering RNA (siRNA) Therapy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padda</surname>
            <given-names>Inderbir S.</given-names>
          </name>
          <aff>Richmond University Medical Center/Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahtani</surname>
            <given-names>Arun U.</given-names>
          </name>
          <aff>Richmond University Medical Center/Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Inderbir Padda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arun Mahtani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-143337.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This activity focuses on small interfering RNA (siRNA) therapy, exemplified by FDA-approved agents such as patisiran, givosiran, lumasiran, inclisiran, nedosiran, and vutrisiran. These therapies are pivotal in managing rare metabolic ailments, including hereditary transthyretin amyloidosis (hATTR), acute hepatic porphyria (AHP), primary hyperoxaluria type 1 (PH1), and lowering low-density lipoprotein cholesterol (LDL-C) in subjects with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD). The activity will&#x000a0;discuss the mechanism of action of siRNA, its adverse event profile, and other key factors essential for interprofessional team members involved in patient care. Furthermore, participants will gain insights into administration techniques, contraindications, clinical toxicology, and monitoring strategies necessary to safely and effectively utilize siRNA therapies in clinical practice.</p>
        <p>Understanding the intricate pharmacology of siRNA is crucial for healthcare professionals to deliver precise therapeutic interventions in various clinical scenarios. This activity equips participants with comprehensive knowledge encompassing the mechanism of action, potential adverse reactions, and contraindications, empowering them to integrate advanced therapeutic strategies into patient care. This comprehension ensures that professionals possess the requisite expertise to provide optimal and innovative patient care within the dynamic realm of medical science, thereby enhancing patient outcomes and contributing to the advancement of medical practice.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Evaluate&#x000a0;the mechanism of action of small interfering RNA (siRNA)-based therapies.</p></list-item><list-item><p>Identify the appropriate monitoring for patients receiving small interfering RNA (siRNA)-based therapies.</p></list-item><list-item><p>Assess the potential adverse effects of small interfering RNA (siRNA)-based therapies.</p></list-item><list-item><p>Implement&#x000a0;interprofessional team strategies for improving care coordination and communication to advance small interfering RNA (siRNA)-based therapies in treating patients with&#x000a0;various conditions.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=143337&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=143337">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-143337.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Small interfering ribonucleic acid (siRNA)-based therapies have been&#x000a0;developed for the past 20 years. The first siRNA agent, patisiran, received US Food Drug Administration (FDA) approval in 2018. To date, the FDA has approved&#x000a0;6 siRNA agents: patisiran, givosiran, lumasiran, inclisiran, nedosiran and vutisiran.</p>
        <p>Patisiran was the first siRNA agent to receive approval from the FDA on August 10, 2018, and is indicated in adult subjects with polyneuropathy due to hereditary transthyretin amyloidosis (hATTR).<xref ref-type="bibr" rid="article-143337.r1">[1]</xref> A year later, givosiran was the second&#x000a0;siRNA agent to receive approval by the FDA.&#x000a0;Patisiran&#x000a0;was indicated in adult subjects with acute hepatic porphyria (AHP).<xref ref-type="bibr" rid="article-143337.r2">[2]</xref>&#x000a0;Lumasiran&#x000a0;was the third&#x000a0;siRNA agent to receive approval by the FDA on November 23, 2020 and was to be used in pediatric and adult subjects with primary hyperoxaluria type 1 (PH1) and reduced urinary oxalate levels.<xref ref-type="bibr" rid="article-143337.r3">[3]</xref>&#x000a0;The siRNA agent to receive FDA approval on December&#x000a0;21, 2021 was inclisiran. The agent is indicated in adult subjects with heterozygous familial hypercholesterolemia (HeFH)/clinical atherosclerotic cardiovascular disease (ASCVD) and lowers the levels of&#x000a0;LDL-C.<xref ref-type="bibr" rid="article-143337.r4">[4]</xref>&#x000a0;</p>
        <p>According to the American Heart Association/American College of Cardiology, in patients with clinical cardiovascular disease on maximally tolerated statin therapy and having LDL-C levels &#x02265;70 mg/dL and when ezetimibe and PCSK9 monoclonal antibody are considered insufficient or not tolerated, it may be helpful to add bempedoic acid/inclisiran (in place of PCSK9 monoclonal antibody) to reduce LDL-C levels additionally.<xref ref-type="bibr" rid="article-143337.r5">[5]</xref></p>
        <p>In accordance with the 2022 AHA/ACC/HFSA guidelines, available data indicates that patisiran is associated with a slowed progression of amyloidosis-related polyneuropathy in individuals with hereditary transthyretin-mediated amyloidosis with cardiomyopathy (ATTRv-CM).<xref ref-type="bibr" rid="article-143337.r6">[6]</xref></p>
        <p>Nedosiran exerts its effects by acting on the hepatic enzyme lactate dehydrogenase, whereas lumasiran acts on the hepatic enzyme glyoxylate oxidase.&#x000a0;Nedosiran and vutrisiran have recently received FDA approval. Vutisiran is now FDA-approved&#x000a0;transthyretin-directed small interfering RNA indicated for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.<xref ref-type="bibr" rid="article-143337.r7">[7]</xref> Nedosiran injection has received FDA approval for the treatment of primary hyperoxaluria type 1 in both children (9 and older) and adults.<xref ref-type="bibr" rid="article-143337.r8">[8]</xref></p>
        <p>Other siRNA-based therapies are currently being evaluated in clinical trials (fitusiran, teprasiran, cosdosiran, and tivanisiran). Other ailments&#x000a0;currently being assessed for management with siRNA-based therapies include hemophilia A and hemophilia B (fitusiran), prophylactic therapy for acute kidney injury (AKI) in patients undergoing transplantation or following cardiovascular surgery (teprasiran), nonarteritic anterior ischemic optic neuropathy, and primary angle glaucoma (cosdosiran), ocular pain and dry eye disease (tivanisiran).<xref ref-type="bibr" rid="article-143337.r9">[9]</xref></p>
        <p>Indications can be summarized below.</p>
        <table-wrap id="article-143337.table0" position="float" orientation="portrait">
          <table border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr style="height: 22.6px;">
                <td style="height: 22.6px;" rowspan="1" colspan="1">
<bold>Drug</bold>
</td>
                <td style="height: 22.6px;" rowspan="1" colspan="1">
<bold>Indication</bold>
</td>
              </tr>
              <tr style="height: 22.6px;">
                <td style="height: 22.6px;" rowspan="1" colspan="1">Patisiran</td>
                <td style="height: 22.6px;" rowspan="1" colspan="1">Polyneuropathy of hereditary transthyretin-mediated amyloidosis</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Givosiran</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Acute hepatic porphyria</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Lumasiran</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Primary hyperoxaluria type 1</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Inclisiran</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH)</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Vutrisiran</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Polyneuropathy of hereditary transthyretin-mediated amyloidosis</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Nedosiran</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Primary hyperoxaluria type 1</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-143337.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The siRNAs are identified as small double-stranded RNAs that exert their effects by dividing into single strands and binding to their distinct target messenger RNA (mRNA) sequences. This action catalyzes a string of activities that yield the target mRNA to&#x000a0;degrade, further halting translation and inducing gene suppression by the short RNA strands.&#x000a0;This enzyme is also known&#x000a0;as RNA interference (RNAi).<xref ref-type="bibr" rid="article-143337.r9">[9]</xref><xref ref-type="bibr" rid="article-143337.r10">[10]</xref></p>
        <p>The siRNA agents initiate their RNAi action in the cytoplasm with the help of an enzyme, endoribonuclease dicer, also known as helicase, with an RNase motif.&#x000a0;Helicase cleaves the double-stranded RNA and yields a siRNA.</p>
        <p>The short double-strand RNA fragments integrate with a cluster of essential proteins known as the RNA-induced silencing complex (RISC) and are then split into&#x000a0;2 single RNA strands recognized as sense and antisense. The single antisense strand further targets its mRNA arrangement while the sense strand is dismissed from the complex.&#x000a0;The essential enzymes in the RISC complex, such as the Ago-2 endonucleases, cleave their target mRNA sequence once affixed.<xref ref-type="bibr" rid="article-143337.r9">[9]</xref><xref ref-type="bibr" rid="article-143337.r10">[10]</xref><xref ref-type="bibr" rid="article-143337.r11">[11]</xref></p>
        <p><bold>Patisiran:&#x000a0;</bold>Patisiran exerts its mechanism of action through RNAi, resulting in cleavage and breakdown of all types (mutant and wild-type) of transthyretin (TTR) mRNA. The agent is a&#x000a0;double-stranded siRNA&#x000a0;formulated as a lipid nanoparticle (LNP) taken up by hepatocytes once bound to apolipoprotein E (APOE)&#x000a0;receptors. The TTR mRNA's RNAi decreases the TTR protein's circulation production and deposition in tissues and organs.<xref ref-type="bibr" rid="article-143337.r12">[12]</xref><xref ref-type="bibr" rid="article-143337.r13">[13]</xref></p>
        <p><bold>Givosiran:&#x000a0;</bold>Givosiran exerts its mechanism of action through RNAi, resulting in the cleavage and breakdown of its target, aminolevulinate synthase 1 (ALAS1) mRNA, found in the liver. The agent is a double-stranded siRNA conjugated&#x000a0;with <italic toggle="yes">N</italic>-acetylgalactosamine (GalNAc) ligand for hepatocyte intake. Once taken up by hepatocytes and degrading its target mRNA, it decreases aminolevulinic acid (ALA) and porphobilinogen (PBG) levels in the blood, further limiting AHP disease characteristics.<xref ref-type="bibr" rid="article-143337.r14">[14]</xref><xref ref-type="bibr" rid="article-143337.r2">[2]</xref></p>
        <p><bold>Lumasiran:&#x000a0;</bold>Lumasiran exerts its mechanism of action through RNAi in the liver, resulting in cleavage and breakdown of its target, hydroxy acid oxidase 1 (HAO1) mRNA. The agent is a double-stranded siRNA conjugated&#x000a0;with GalNAc&#x000a0;ligand&#x000a0;for effective hepatocyte uptake.&#x000a0;HAO1 produces glycolate oxidase (GO), an enzyme responsible for producing glyoxylate, a substrate for the further synthesis of oxalate. The inhibition of the GO enzyme results in decreased oxalate precursor levels, reducing the production of the enzyme alanine glyoxylate aminotransferase (AGT) that is mutated in PH1.<xref ref-type="bibr" rid="article-143337.r9">[9]</xref><xref ref-type="bibr" rid="article-143337.r15">[15]</xref><xref ref-type="bibr" rid="article-143337.r14">[14]</xref></p>
        <p><bold>Inclisiran:&#x000a0;</bold>Inclisiran exerts its mechanism of action through RNAi in the liver and orchestrates hepatic mRNA degradation of proprotein convertase subtilisin/kexin type-9 (PCSK9). The sense strand of the siRNA is bound with the GalNAc&#x000a0;ligand, allowing hepatocytes to uptake the siRNA agent and target PCSK9 efficiently. PCSK9 internalizes and breaks down the hepatic LDL receptors once attached. Inclisiran inhibits this action of PCSK9, further promoting the expression of LDL-C receptors on the cell's surface and facilitating receptor cycling. Once LDL-C is bound to its receptor, it is subject to degradation by lysosomal enzymes and recycled back to the cell's surface. This results in a raised uptake of LDL-C and reduces its levels in the blood.<xref ref-type="bibr" rid="article-143337.r16">[16]</xref></p>
        <p><bold>Nedosiran:&#x000a0;</bold>Nedosiran, a double-stranded small interfering RNA (siRNA) conjugated to GalNAc aminosugar residues, is administered subcutaneously. Upon administration, the GalNAc-conjugated sugars bind to asialoglycoprotein receptors (ASGPR), facilitating nedosiran delivery to hepatocytes. The siRNA action of nedosiran leads to the degradation of hepatic lactate dehydrogenase (LDH) by targeting LDHA messenger ribonucleic acid (mRNA) through RNA interference. This reduction in hepatic LDH levels diminishes oxalate production by the liver, subsequently&#x000a0;reducing the oxalate burden.<xref ref-type="bibr" rid="article-143337.r17">[17]</xref></p>
        <p><bold>Vutrisiran:&#x000a0;</bold>Vutrisiran, a double-stranded small interfering RNA (siRNA) with a GalNAc conjugate, induces the degradation of mutant and wild-type transthyretin (TTR) mRNA through RNA interference. This mechanism leads to a decrease in serum TTR protein levels and the deposition of TTR protein in tissues.<xref ref-type="bibr" rid="article-143337.r7">[7]</xref></p>
      </sec>
      <sec id="article-143337.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms, Strengths and Dosage</bold>
</p>
        <p>
<bold>Patisiran</bold>
</p>
        <p>Patisiran is available&#x000a0;and distributed as a single-dose vial of 10 mg/5 mL (2 mg/mL). A lipid complex injection should be filtered and diluted before administering. A healthcare professional should calculate and adjust the correct dosage according to the patient's body weight and&#x000a0;administer it as an intervenous infusion.</p>
        <p>Indication: polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.</p>
        <list list-type="bullet">
          <list-item>
            <p>0.3 mg/kg once every&#x000a0;3 weeks (weight &#x0003c;100 kg)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>30 mg once every&#x000a0;3 weeks (weight &#x02265;100 kg)</p>
          </list-item>
        </list>
        <p>Patisiran should be administered immediately if an&#x000a0;earlier dose was missed. Patients given&#x000a0;a dose within&#x000a0;3 days from a missed dosage should&#x000a0;follow their original regime.&#x000a0;</p>
        <p>Patients receiving&#x000a0;treatment with patisiran are advised to receive&#x000a0;premedication therapy 60 minutes before&#x000a0;administration of the IV infusion to decrease the occurrence of infusion-related reactions (IRRs). Premedication therapies consist of corticosteroids (IV), acetaminophen (oral), H1 blockers (IV), and H2 blockers (IV).</p>
        <p>
<bold>Givosiran</bold>
</p>
        <p>Givosiran is available and distributed as a single-dose vial of&#x000a0;189 mg/mL for subcutaneous injection.</p>
        <p>Indication: acute hepatic porphyria in adults.</p>
        <list list-type="bullet">
          <list-item>
            <p>2.5 mg/kg once monthly</p>
          </list-item>
        </list>
        <p>Givosiran should be administered immediately if a prior dosage was missed and continued monthly afterward. Patients with critical elevations in liver transaminases should decrease their dosage to&#x000a0;1.25 mg/kg every month. In subjects who do not show a recurring increase in&#x000a0;transaminases while receiving therapy at 1.25 mg/kg, the dosage can be increased to 2.5 mg/kg.</p>
        <p>
<bold>Lumasiran</bold>
</p>
        <p>Lumasiran&#x000a0;is available and distributed as a single-dose vial&#x000a0;of&#x000a0;94.5 mg/0.5 mL for subcutaneous injection.&#x000a0;Lumasiran is administered as&#x000a0;loading doses accompanied by&#x000a0;maintenance doses calculated and adjusted according to the patient's body weight.</p>
        <p>Indication: PH1 adult and pediatric subjects.</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial loading dose: 6 mg/kg administered&#x000a0;once a month for&#x000a0;3 doses (weight &#x0003c;10 kg)</p>
          </list-item>
          <list-item>
            <p>Maintenance dose: 3 mg/kg administered once a month (weight&#x000a0;&#x0003c;10 kg)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Initial loading dose: 6 mg/kg administered once a month&#x000a0;for&#x000a0;3 doses (10 to 20 kg)</p>
          </list-item>
          <list-item>
            <p>Maintenance dose:&#x000a0;6 mg/kg administered once every&#x000a0;3 months quarterly&#x000a0;(10 to 20 kg)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Initial loading dose: 3 mg/kg administered once a month for&#x000a0;3 doses (&#x02265;20 kg)</p>
          </list-item>
          <list-item>
            <p>Maintenance dose: 3 mg/kg administered once every&#x000a0;3 months (&#x02265;20 kg)</p>
          </list-item>
        </list>
        <p>Lumasiran should be administered immediately if a prior dosage was missed and continued monthly thereafter.</p>
        <p>
<bold>Inclisiran</bold>
</p>
        <p>Inclisiran is available and distributed as a pre-filled single-dose vial of 284 mg/1.5 mL (189 mg/mL) for subcutaneous injection.&#x000a0;&#x000a0;</p>
        <p>Indication: reducing LDL-C in subjects with HeFH or ASCVD&#x000a0;adjunctive to diet and statin therapy tolerated at a maximum dose.</p>
        <list list-type="bullet">
          <list-item>
            <p>284 mg (initial dose)</p>
          </list-item>
          <list-item>
            <p>284 mg (at&#x000a0;3 months)</p>
          </list-item>
          <list-item>
            <p>284 mg (every&#x000a0;6 months after that)</p>
          </list-item>
        </list>
        <p>Inclisiran should be administered immediately if a prior dosage was missed. Patients given&#x000a0;a dosage within&#x000a0;3 months of a missed dosage are recommended to&#x000a0;follow their original regime. If a dose&#x000a0;has been missed for&#x000a0;more than&#x000a0;3 months, therapy&#x000a0;should be initiated at&#x000a0;3 months&#x000a0;following administration of the missed dosage and every&#x000a0;6 months after that.</p>
        <p>
<bold>Nedosiran</bold>
</p>
        <p>Nedosiran is available in 128mg/0.8 mL as a single-dose pre-filled syringe and 160 mg/mL as a single-dose pre-filled syringe, both intended for subcutaneous injection.</p>
        <p>Indication: Lower urinary oxalate levels are reduced in individuals aged 9 and older with primary hyperoxaluria type 1 (PH1) and preserved kidney function (eGFR &#x02265; 30 mL/min/1.73 m2).</p>
        <list list-type="bullet">
          <list-item>
            <p>Adults and Adolescents (age 12 and older)</p>
            <list list-type="bullet">
              <list-item>
                <p>Greater than or equal to 50 kg: 160 mg once monthly (pre-filled syringe, 1 mL)</p>
              </list-item>
              <list-item>
                <p>Less than 50 kg: 128 mg once monthly (pre-filled syringe, 0.8 mL)</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Children (ages 9 to 11)</p>
            <list list-type="bullet">
              <list-item>
                <p>Greater than or equal to 50 kg: 160 mg once monthly (pre-filled syringe, 1 mL)</p>
              </list-item>
              <list-item>
                <p>Less than 50 kg: 3.3 mg/kg once monthly, not to exceed 128 mg (round to nearest 0.1 mL)</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Vutrisiran</bold>
</p>
        <p>Vutisiran is available as a single-dose pre-filled syringe containing 25 mg/0.5 mL for subcutaneous injection.</p>
        <p>Indication:&#x000a0;Polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.</p>
        <list list-type="bullet">
          <list-item>
            <p>Recommended Dosage:&#x000a0;25 mg administered by subcutaneous injection once every 3 months.</p>
          </list-item>
        </list>
        <p>It is recommended that the recommended amount of vitamin A be supplemented daily while taking vutrisiran. If any ocular symptoms that suggest a vitamin A deficiency occur, it is recommended to consult an ophthalmologist.<xref ref-type="bibr" rid="article-143337.r7">[7]</xref></p>
      </sec>
      <sec id="article-143337.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse events are listed by the agent below.<xref ref-type="bibr" rid="article-143337.r16">[16]</xref></p>
        <p>
<bold>Patisiran</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Upper respiratory tract infections (URTI) (28%)</p>
          </list-item>
          <list-item>
            <p>Infusion-related reactions (19%)</p>
          </list-item>
          <list-item>
            <p>Dyspepsia&#x000a0;(8%)</p>
          </list-item>
          <list-item>
            <p>Dyspnea&#x000a0;(8%)</p>
          </list-item>
          <list-item>
            <p>Muscle spasms&#x000a0;(8%)</p>
          </list-item>
          <list-item>
            <p>Arthralgia&#x000a0;(7%)</p>
          </list-item>
          <list-item>
            <p>Erythema (7%)</p>
          </list-item>
          <list-item>
            <p>Bronchitis (7%)</p>
          </list-item>
          <list-item>
            <p>Vertigo&#x000a0;(5%)</p>
          </list-item>
        </list>
        <p>
<bold>Givosiran</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nausea (27%)</p>
          </list-item>
          <list-item>
            <p>Injection site reactions (25%)</p>
          </list-item>
          <list-item>
            <p>Rash (17%)</p>
          </list-item>
          <list-item>
            <p>Serum creatinine increase (15%)</p>
          </list-item>
          <list-item>
            <p>Elevated liver transaminases (13%)</p>
          </list-item>
          <list-item>
            <p>Fatigue (10%)</p>
          </list-item>
        </list>
        <p>
<bold>Lumasiran</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Injection site reactions (38%)</p>
          </list-item>
          <list-item>
            <p>Abdominal pain/discomfort (15%)</p>
          </list-item>
        </list>
        <p>
<bold>Inclisiran</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Arthralgia (4%)</p>
          </list-item>
          <list-item>
            <p>Urinary tract infection (3.6%)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Diarrhea (3.5%)</p>
          </list-item>
          <list-item>
            <p>Bronchitis (2.7%)</p>
          </list-item>
          <list-item>
            <p>Pain in extremity&#x000a0;(2.6%)</p>
          </list-item>
          <list-item>
            <p>Dyspnea (2.6%)</p>
          </list-item>
          <list-item>
            <p>Injection site reaction (1.8%)</p>
          </list-item>
        </list>
        <p>
<bold>Nedosiran</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Injection site reactions (&#x02265;20%)&#x000a0;<xref ref-type="bibr" rid="article-143337.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Vutrisiran</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pain in extremity (15%)</p>
          </list-item>
          <list-item>
            <p>Arthralgia (11%)</p>
          </list-item>
          <list-item>
            <p>Dyspnea (7%)</p>
          </list-item>
          <list-item>
            <p>Vitamin A deficiency (7%)&#x000a0;<xref ref-type="bibr" rid="article-143337.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Injection site reactions (4%)</p>
          </list-item>
          <list-item>
            <p>Rare case report of atrioventricular block.<xref ref-type="bibr" rid="article-143337.r19">[19]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-143337.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>No labeled contraindications have been reported for patisiran, lumasiran, neodosiran, vutisiran and inclisiran. Hypersensitivity to givosiran is an absolute contraindication to therapy.<xref ref-type="bibr" rid="article-143337.r20">[20]</xref>&#x000a0;Anaphylaxis&#x000a0;has been&#x000a0;reported in&#x000a0;&#x0003c;1% of subjects during clinical trials with givosiran.<xref ref-type="bibr" rid="article-143337.r21">[21]</xref></p>
      </sec>
      <sec id="article-143337.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients receiving therapy with patisiran should be monitored for infusion-related adverse responses such as hypersensitivity reactions and anaphylaxis. Treatment with patisiran should be delayed or interrupted, and appropriate management should be initiated as clinically required. Infusion should be resumed gradually once adverse manifestations are resolved. In the event of critical infusion-related adverse responses, therapy should not be continued.&#x000a0;Patients receiving treatment with patisiran should also have their vitamin A levels monitored routinely as therapy decreases its levels. Patients should be initiated on vitamin A supplementation that does not exceed the recommended daily dosage and monitored for clinical manifestations of vitamin A deficiency.<xref ref-type="bibr" rid="article-143337.r22">[22]</xref></p>
        <p>Liver function tests (LFTs) should be monitored at baseline and routinely after that in patients receiving treatment with givosiran, as an increase in alanine transaminase (ALT) was observed during clinical trials. Elevation in liver function is reported to occur around 3 to 5 months from the initiation of therapy. Recommendations are to measure LFTs monthly for the first&#x000a0;6 months of givosiran. Treatment should be discontinued in patients with severe elevations in ALT. Baseline and routine monitoring of estimated glomerular filtration rate (eGFR) and serum creatinine levels is recommended along with LFTs when receiving givosiran. Alterations in eGFR and creatinine were reported during clinical trials.</p>
        <p>Patients receiving givosiran should also have their homocysteine levels measured at baseline and routinely afterward. Elevations in homocysteine levels in the blood were reported in 16% of subjects during clinical trials. Patients with evidence of homocysteine elevations should have their vitamin B9 and B12 levels assessed and consider initiating vitamin B6 supplementation.</p>
        <p>Immunogenicity with all siRNA agents is possible and may be a barrier to therapeutic delivery. An unwanted biological immunogenic response may identify siRNA as a viral RNA antigen, provoking undesirable adverse reactions. During clinical trials, anti-drug antibodies (ADA) developed in 3.6% of subjects receiving patisiran, 6% of subjects receiving lumasiran, 0.9% of subjects receiving givosiran, 1.8% of subjects before inclisiran dosing, and 4.9% of subjects at 18 months therapy. ADA did not influence effectiveness or safety in all siRNA agents, resulting in no clinically significant discrepancies in the pharmacokinetics and pharmacodynamics.<xref ref-type="bibr" rid="article-143337.r23">[23]</xref></p>
      </sec>
      <sec id="article-143337.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>During clinical trials with givosiran, hepatic and renal toxicity was reported. Fifteen percent of subjects receiving therapy reported ALT elevations&#x000a0;3 times above the normal range. Fifteen percent of subjects reported elevated serum creatinine levels and reductions in eGFR, with a median elevation in creatinine of 0.07 mg/dL at&#x000a0;3 months. The severity of laboratory alterations and clinical symptoms should determine whether to continue therapy.&#x000a0;</p>
        <p>
<bold>Pregnancy</bold>
</p>
        <p>Data on using patisiran and lumasiran therapy during pregnancy has not been reported. A reduction in vitamin A levels is recognized with patisiran use, a crucial component of normal embryo maturation and fetal development. An excess in vitamin A levels correlates with adverse effects on the fetus.&#x000a0;</p>
        <p>Although givosiran was not studied in humans during pregnancy, animal reproduction analyses demonstrated unfavorable developmental effects during organogenesis. Givosiran during pregnancy should be assessed, weighing the advantages and dangers to the mother and probable impacts on the developing fetus.&#x000a0;Inclisiran therapy is recommended to be discontinued during pregnancy. This agent's mechanism of action has been reported to decrease cholesterol, and biologically active substances may harm the developing fetus.<xref ref-type="bibr" rid="article-143337.r24">[24]</xref></p>
      </sec>
      <sec id="article-143337.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Small interfering ribonucleic acid (siRNA) based therapies have&#x000a0;recently&#x000a0;been approved as therapeutics exerting their effects by RNAi on their target mRNA in the liver. To date,&#x000a0;6 agents (patisiran, givosiran, lumasiran, inclisiran, nedosiran, and vutisiran) are FDA-approved for managing adult patients with hATTR, AHP, reducing LDL-C in subjects with HeFH or ASCVD, and PH1 in adults and pediatric patients. Caring for patients with rare metabolic ailments demands care coordination from a team of healthcare professionals. The healthcare team should include a primary care physician (PCP), a hematologist, a nephrologist, a cardiologist, a physician assistant, a nurse practitioner, a clinical geneticist, nurses, and a pharmacist.</p>
        <p>The healthcare team should conduct a thorough clinical examination to assess if the management of siRNA-based therapies suits the patient. Before prompting treatment, the interprofessional team should determine the patient's laboratory values, such as renal and liver function (givosiran), lipid levels (inclisiran), and vitamin A levels (patisiran, vutisiran) at baseline and&#x000a0;periodically.&#x000a0;The PCP should regularly communicate with the other specialists caring for such patients.</p>
        <p>The healthcare team should administer the abovementioned premedications (corticosteroid, acetaminophen, H1 blocker, and&#x000a0;H2 blocker) at least 60 minutes before the infusion to prevent an infusion-related reaction. The prescribing and administering clinician should be prepared and equipped for immediate adverse effects such as infusion-related hypersensitivity reactions. The healthcare team should monitor for headaches, back pain, abdominal pain, shortness of breath, and nausea during infusion. In the event of clinical signs such as hypotension, syncope, and anaphylaxis, the infusion should be discontinued immediately, and appropriate symptomatic management should be initiated.</p>
        <p>The interprofessional team should educate their patients on the probable adverse effects of siRNA-based therapies and counsel them regarding the appropriate measures. Vitamin A levels&#x000a0;require routine monitoring by the prescribing healthcare provider for patients receiving patisiran and vutisiran, as the agents are reported to decrease their levels.</p>
        <p>Childbearing females considering treatment with siRNA-based therapies during pregnancy should be evaluated to determine the benefits and risks before starting therapy. Although no studies and data involving pregnant women have been reported, pregnancy risks&#x000a0;merit discussion. Patisiran reportedly decreases vitamin A levels, which is essential for fetal development. Excess vitamin A levels may also cause adverse developmental consequences. Pregnant patients considering givosiran should be informed about unfavorable fetal developmental outcomes during organogenesis in animal models. Inclisiran should be discontinued during pregnancy.&#x000a0;Effective communication among the primary healthcare team and specialists treating patients with siRNA-based therapies can reduce complications and enhance quality of life and patient outcomes.<xref ref-type="bibr" rid="article-143337.r9">[9]</xref><xref ref-type="bibr" rid="article-143337.r11">[11]</xref></p>
      </sec>
      <sec id="article-143337.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=143337&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=143337">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/143337/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=143337">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-143337.s11">
        <title>References</title>
        <ref id="article-143337.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urits</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Swett</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berardino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Amgalan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kassem</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Viswanath</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>A Review of Patisiran (ONPATTRO&#x000ae;) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis.</article-title>
            <source>Neurol Ther</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>301</fpage>
            <page-range>301-315</page-range>
            <pub-id pub-id-type="pmid">32785879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Syed</surname>
                <given-names>YY</given-names>
              </name>
            </person-group>
            <article-title>Givosiran: A Review in Acute Hepatic Porphyria.</article-title>
            <source>Drugs</source>
            <year>2021</year>
            <month>May</month>
            <volume>81</volume>
            <issue>7</issue>
            <fpage>841</fpage>
            <page-range>841-848</page-range>
            <pub-id pub-id-type="pmid">33871817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Keam</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Lumasiran: First Approval.</article-title>
            <source>Drugs</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>81</volume>
            <issue>2</issue>
            <fpage>277</fpage>
            <page-range>277-282</page-range>
            <pub-id pub-id-type="pmid">33405070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albosta</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Taub</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Michos</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2023</year>
            <volume>19</volume>
            <fpage>421</fpage>
            <page-range>421-431</page-range>
            <pub-id pub-id-type="pmid">37434791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Writing Committee Members</collab>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Bittner</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Demeter</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Fearon</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Kazi</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kolte</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kumbhani</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>LoFaso</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mahtta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mark</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Minissian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Navar</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Piano</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Talbot</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Taqueti</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>van Diepen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wiggins</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic&#x000a0;Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2023</year>
            <month>Aug</month>
            <day>29</day>
            <volume>82</volume>
            <issue>9</issue>
            <fpage>833</fpage>
            <page-range>833-955</page-range>
            <pub-id pub-id-type="pmid">37480922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>145</volume>
            <issue>18</issue>
            <fpage>e895</fpage>
            <page-range>e895-e1032</page-range>
            <pub-id pub-id-type="pmid">35363499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Heo</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Shirley</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.</article-title>
            <source>Drugs</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>83</volume>
            <issue>15</issue>
            <fpage>1425</fpage>
            <page-range>1425-1432</page-range>
            <pub-id pub-id-type="pmid">37728865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al Shaer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Al Musaimi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Albericio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>de la Torre</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>2023 FDA TIDES (Peptides and Oligonucleotides) Harvest.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2024</year>
            <month>Feb</month>
            <day>13</day>
            <volume>17</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">38399458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bahal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Manautou</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>XB</given-names>
              </name>
            </person-group>
            <article-title>The growth of siRNA-based therapeutics: Updated clinical studies.</article-title>
            <source>Biochem Pharmacol</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>189</volume>
            <fpage>114432</fpage>
            <pub-id pub-id-type="pmid">33513339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agrawal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dasaradhi</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Mohmmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bhatnagar</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>RNA interference: biology, mechanism, and applications.</article-title>
            <source>Microbiol Mol Biol Rev</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>657</fpage>
            <page-range>657-85</page-range>
            <pub-id pub-id-type="pmid">14665679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Springer</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Dowdy</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.</article-title>
            <source>Nucleic Acid Ther</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>109</fpage>
            <page-range>109-118</page-range>
            <pub-id pub-id-type="pmid">29792572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoy</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Patisiran: First Global Approval.</article-title>
            <source>Drugs</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>78</volume>
            <issue>15</issue>
            <fpage>1625</fpage>
            <page-range>1625-1631</page-range>
            <pub-id pub-id-type="pmid">30251172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>95</fpage>
            <page-range>95-99</page-range>
            <pub-id pub-id-type="pmid">30644768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Allard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Darcy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chigas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bond</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Janas</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs.</article-title>
            <source>Nucleic Acid Ther</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>309</fpage>
            <page-range>309-315</page-range>
            <pub-id pub-id-type="pmid">33861634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDougall</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramsden</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aluri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Arciprete</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Castellanos-Rizaldos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Charisse</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cichocki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guenther</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Habtemariam</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jadhav</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Janas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jayaraman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kurz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maclauchlin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Manoharan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Robbie</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Theile</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vaishnaw</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Waldron</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zlatev</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of <italic>N</italic>-Acetylgalactosamine-Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>781</fpage>
            <page-range>781-797</page-range>
            <pub-id pub-id-type="pmid">34154993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamb</surname>
                <given-names>YN</given-names>
              </name>
            </person-group>
            <article-title>Inclisiran: First Approval.</article-title>
            <source>Drugs</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>389</fpage>
            <page-range>389-395</page-range>
            <pub-id pub-id-type="pmid">33620677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldfarb</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Lieske</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Groothoff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schalk</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vrhnjak</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).</article-title>
            <source>Urolithiasis</source>
            <year>2023</year>
            <month>Apr</month>
            <day>28</day>
            <volume>51</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <pub-id pub-id-type="pmid">37118061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Syed</surname>
                <given-names>YY</given-names>
              </name>
            </person-group>
            <article-title>Nedosiran: First Approval.</article-title>
            <source>Drugs</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>83</volume>
            <issue>18</issue>
            <fpage>1729</fpage>
            <page-range>1729-1733</page-range>
            <pub-id pub-id-type="pmid">38060091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia-Pavia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Concei&#x000e7;&#x000e3;o</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Di Carli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yureneva</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gillmore</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>397</fpage>
            <page-range>397-410</page-range>
            <pub-id pub-id-type="pmid">38321786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ventura</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Gouya</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aguilera-Peir&#x000f3;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Montgomery Bissell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Balwani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>DKE</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kuter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Monroy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ritchie</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hua</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sweetser</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Sardh</surname>
                <given-names>E</given-names>
              </name>
              <collab>ENVISION Investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.</article-title>
            <source>Liver Int</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>161</fpage>
            <page-range>161-172</page-range>
            <pub-id pub-id-type="pmid">34717041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <chapter-title>Givosiran</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>2</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">32200604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rizk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>T&#x000fc;zmen</surname>
                <given-names>&#x0015e;</given-names>
              </name>
            </person-group>
            <article-title>Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran.</article-title>
            <source>Pharmgenomics Pers Med</source>
            <year>2017</year>
            <volume>10</volume>
            <fpage>267</fpage>
            <page-range>267-278</page-range>
            <pub-id pub-id-type="pmid">29184431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic reversal of Huntington's disease by in vivo self-assembled siRNAs.</article-title>
            <source>Brain</source>
            <year>2021</year>
            <month>Dec</month>
            <day>16</day>
            <volume>144</volume>
            <issue>11</issue>
            <fpage>3421</fpage>
            <page-range>3421-3435</page-range>
            <pub-id pub-id-type="pmid">34918046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143337.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tkaczuk</surname>
                <given-names>KHR</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Metformin Bicarbonate-Mediated Efficient RNAi for Precise Targeting of <italic>TP53</italic> Deficiency in Colon and Rectal Cancers.</article-title>
            <source>Nano Today</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>43</volume>
            <pub-id pub-id-type="pmid">35251293</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
